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Sllmrllary 
We analyzed the stimulatory effect of oncostatin M (OSM), leukemia inhibitory factor (LIF), 
interleukin 6 (IL-6), IL-11, and the inhibitory effect of anti-IL-6 antibody (Ab), anti-IL-6 receptor 
monoclonal antibody (mAb), and anti-gp130 mAb on the growth of human plasmacytoma cells 
freshly isolated from a patient with multiple myeloma. The purified cells showed a plasmacytoid 
morphology and expressed CD38, CD54, and CD56 antigens but no CD3, CDS, CD10, CD19, 
CD20, or very late antigen 5. IL-6 receptor (IL-6R) and its signal transducer, gp130, were expressed 
on their cell surface at a low level. Dose-dependent proliferation of the cells in response to OSM, 
LIF, and IL-6, but not to IL-11, was observed using [3H]TdR incorporation in vitro. Both anti- 
IL-6 Ab and anti-IL-6K mAb inhibited the growth of the cells in the presence or absence of 
exogenous IL-6. These cells release IL-6 but not OSM or LIF into the culture supernatant during 
short-term culture. Therefore, an autocrine growth mechanism mediated by IL-6,  but not by 
OSM or LIF, was confirmed. Furthermore, anti-gp130 mAb completely inhibited the proliferation 
of the cells induced by OSM, LIF, as well as IL-6. These data indicate that OSM, LIE and IL-6 
can act as growth factors of human plasmacytoma cells through a common signal transducer, 
gp130, on their cell surface, and also suggest the potential therapeutic application of anti-gp130 
mAb, as well as anti-IL-6R mAb against myeloma/plasmacytomas. 
I 
L-6, a pleiotropic cytokine with a wide range of biological 
activities  (1), is a potent growth factor for murine plas- 
macytoma cells and human myeloma cells (2-5). Studies on 
human myeloma cells freshly isolated from the bone marrow 
of patients demonstrate that IL-6 is an autocrine as well as 
paracrine growth factor in human multiple myeloma (4, 5). 
On the basis of this finding, Klein et al. (6) showed that the 
in vivo administration of routine anti-IL-6 mAb to a patient 
with plasma cell leukemia was therapeutically effective. 
IL-11 was originally described as a factor that promoted 
the growth of a murine plasmacytoma cell line (7). It sup- 
ports the growth of hematopoietic progenitor cells directly 
and synergistically with IL-3, and also promotes both human 
and mouse megakaryocyte colony formation (8). 
R~cently oncostatin M (OSM), leukemia inhibitory factor 
(LIF), and ciliary neurotrophic factor (CNTF), as well as IL- 
11, were shown to have multiple biological activities  that 
overlap with one other and with those of IL-6 (8-11). The 
functional redundancy of these cytokines could be explained 
by their sharing the same signal transducing molecule, gp130 
(12,  13). This hypothesis is supported by the finding that 
anti-gp130 mAb can block the synthesis of acute phase pro- 
teins in hepatocytes induced by either IL-6,  LIF, or OSM 
(14) and also block the growth inhibition of melanoma cells 
induced by either IL-6 or OSM (15). From this evidence, it 
seems likely that these cytokines, as well as IL-6, may be 
growth factors of human myeloma/plasmacytoma cells. In 
this study, we report that OSM and LIE as well as IL-6, 
can induce the growth of freshly isolated plasmacytoma cells 
through a common signal transducer,  gp130, on their cell 
surface. 
Materials  and Methods 
Case Report.  A 53-yr-old  male patient initially presented with 
multiple advanced  lytic bone lesions, pathological bone fractures, 
and marrow plasmacytosis  (~35%) with mitotic features. He was 
diagnosed  as having  multiple myeloma,  although no serum M com- 
ponent was detectable. The patient also had extramedullary plas- 
macytoma tumors. Biopsy tissue from an intercostal tumor was 
used for analysis after informed consent was obtained. 
Phenotypical  Analysis of Plasmac?toma Cells.  Plasmacytoma  cells 
were freshly isolated from biopsy tissue and enriched by density 
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glass slides, fixed, and examined for morphology by May-G~nwald-  ~  i ng/ml 
Giemsa's stain and for cytoplasmic  Ig using affinity-purified  FITC-  IL-6  ~  10 ng/ml 
labeled goat Abs specific  for human c<, % #, x, and X  chains  (Cappel  100 ng/ml 
Organon Teknica Co., West Chester, PA). Cell surface Ib6R and  r  1 ng/mt 
gp130 were identified using biotinylated mouse PM1 mAb (ylx  LIF  ~  10 ng/m! 
isotype [17], provided by Chugai Pharmaceutical Co., Shizuoka,  loo ng/ml 
Japan)  and  AM64 mAb  (',/1K [18], provided by  Tosoh Co.,  ~-  l ng/ml 
Kanagawa, Japan), respectively, in conjunction with PE-labeled  OSM  ~  10 ng/m! 
streptavidin. Antihuman very late antigen 5 (VLA-5) o~ chain mAb  loo ng/ml 
(Seikagaku Co., Tokyo,  Japan) was used to identify  cell surface  VLA-  r  1  ng/ml 
5 and was developed with FITC-labeled goat anti-mouse Ig Ab  IL-11  ~  10 ng/ml 
(Zymed Laboratories, Inc., San Francisco, CA). The other surface  lo0 ng/ml 
antigens were detected with FITC- or PE-conjugated anti-CD3, 
anti-CD5, anti-CD10, anti-CD19, anti-CD20, anti-CD38, anti- 
CD54, and anti-CD56 mAbs (Becton Dickinson & Co., Moun- 
tain View, CA). 2  x  10  s cells from single cell suspensions were 
incubated with the appropriate  Ab at a concentration  of  6-50 #g/ml 
for 20 min on ice, washed in PBS with 10% FCS and, if necessary, 
incubated with the  appropriate second-step reagents. Isotype- 
matched Abs with irrelevant specificity  were used as negative con- 
trois. Flow cytometric analysis was performed on a FACScan  | 
(Becton Dickinson & Co.). 
In Vitro Cell  Proliferation  Assay.  Purified  plasmacytoma  cells were 
cultured at a density of 0.3-1  x  106 cells/ml on 96-well plates for 
72 h in 0.2 ml of RPMI-1640 medium supplemented with 10% 
FCS and 5  x  10-s tool/liter 2-ME in the presence or absence of 
recombinant human OSM, LIF, IL6, Ib11, anti-IL-6  Ab (goat anti- 
IL-6 antiserum), humanized anti-IL-61k  mAb (rhPM1 [19]), and/or 
anti-gp130 mAb (gpx22 [20]). In an experiment to test the syner- 
gistic effects  of the cytokines on cell proliferation, various combi- 
nations of the cytokines  were added. DNA synthesis  was measured 
after the last 16-h pulse label of a 72-h culture with 18.5 kBq/well 
of [~H]TdR (370 GBq/mmol; Dupont, Wilmington, DE). OSM 
was purchased from Genzyme Corp. (Cambridge, MA), and LIF 
and ILll were obtained from R&D Systems, Inc. (Minneapolis, 
MN). II.-6  was provided  by Ajinomoto Co. (Kawasaki,  Japan); goat 
anti-IL6 antiserum by the National Biological  Standards Board of 
the World Health Organization; rhPM1 by Chugai Pharmaceu- 
tical Co.; and gpx22 by Tosoh Co. 
Cytokine Assays.  Purified  plasmacytoma  cells were cultured at 
106 cells/ml on 24-well plates for 48-120 h and the culture super- 
natants were harvested for the cytokine assays. I1.-6 was measured  OSM  LIF  IL-6  IL-11 
by a dissociation-enhanced  lanthanide  fluoroimmunoassay  (21). OSM 
and LIF were measured by ELISA (R&D Systems, Inc.). 
Results 
Characterization  of  lsolated  Plasmacytoma Cells.  Greater than 
99% of the freshly purified cells showed plasmacytoid mor- 
phology which can be dassified as plasmablastic type according 
to Greipp's  criteria (22),  and expressed very small amounts 
of intracytoplasmic Ig x light chains. They expressed CD38, 
CD54,  and CD56 antigens but no detectable CD3,  CD5, 
CD10, CD20, or VLA-5 on their cell surface. Low levels of 
IL-6R and gp130  were identified on their cell  surface. 
OSM-, LIF-, and IL-6-dependent Proliferation  of the Plasmacy- 
toma Cells.  When the plasmacytoma cells were cultured with 
OSM, LIF, IL-6, or IL-11 at varying concentrations (1-100 
ng/ml), dose-dependent growth on OSM, LIE and IL-6 was 
observed  (Fig.  1).  100 ng of recombinant OSM, LIF, and 
IL-6 augmented the proliferation by 6,0-, 5.5-, and 1.8-fold, 
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Figure  1.  In vitro  cell  proliferation  analysis  of freshly  isolated  plasmacy- 
toma cells. The cells (6 x 104/200/~l/wdl)  were cultured with varying 
concentrations of recombinant human OSM, LIE Ib6, of Ib11. DNA 
synthesis was measured by [3H]TdR incorporation  after 3 d of culture. 
Dose-dependent proliferation  with OSM, LIF,  and Ib6 but not with IIA1 
was observed. 
respectively.  The stimulatory effect of OSM and LIF was 
stronger than that of IL-6, although 100 ng of these cytokines 
was below the optimal dose. IL-11, however, did not induce 
the growth of plasmacytoma cells as reported in an earlier 
study (23). 
To test for synergistic effects among OSM, LIF, IL-6, and 
IL-11, various combinations of these cytokines were added. 
A  slight  augmentation of [3H]TdR  uptake was  observed 
when the cells were cultured with LIF and IL-6 in addition 
to either OSM or IL-11 (Fig. 2), although it was not signi- 
ficant. 
Inhibition of  Plasmacytoma Cell Growth by Anti-IL-6 At~ Anti- 
IL-6R mAb, and Anti-gp130 mAh  To determine the inhibi- 
tory effect of anti-IL-6 Ab or anti-IL-6R mAb on the growth 
of plasmacytoma cells, the cells were cultured with these Abs 
in the presence or absence of IL-6. In this experiment, hu- 
manized anti-IL-6R mAb (rhPM1) was used for possible ther- 
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Figure  2.  Synergistic  effects  ofcytokines  on the proliferation  of  freshly 
isolated plasmacytoma  cells. DNA synthesis  in the cells (6  x  104/200 
/~l/well)  cultured  with various  combinations  of  OSM, LIF, IL-6,  and II.-11 
(10 ng/ml each) was measured. There seemed  to be no significant  syner- 
gistic effects  with these cytokines. 
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inhibited the spontaneous  growth of plasmacytoma  cells 
(66-80% inhibition, Fig. 3 A [-]), suggesting that IL-6 par- 
ticipates in an autocrine growth mechanism,  rhPM1 could 
also inhibit the proliferation of  the cells even when rlL-6 was 
added exogenously (81-87%  inhibition, Fig. 3 A,  IL-6). 
To confirm that OSM, LIF, and IL-6 stimulate cell growth 
through a common signal transducer, gp130, anti-gp130 mAb 
was used for neutralization. Anti-gpD0 mAb dearly  blocked 
the OSM-, LIF-, and IL-6-dependent growth of plasmacy- 
toma cells (84-97% inhibition, Fig. 3 B). The inhibitory effect 
of anti-gp130 mAb on spontaneous cell growth was almost 
as great as that of anti-IL-6 Ab or anti-IL-6R mAb in vitro, 
suggesting that LIF and OSM were not involved in an auto- 
crine growth of these plasmacytoma cells. 
Cytokine Production by Plasmacytoma Cells.  In the culture 
supernatant  of the plasmacytoma cells, 125 pg/ml of IL-6 
was detected at 48 h and the IL-6 concentration reached 470 
pg/ml at  120 h. However, no detectable levels of OSM or 
LIF were observed in the supernatants  either at 48 or 120 
hours.  (LIF  <15  pg/mI;  OSM  <15  pg/ml).  The  data 
confirmed that these cells respond  to an autocrine growth 
mechanism mediated by IL-6 but not by OSM or LIE 
Discussion 
The data indicate that an autocrine growth mechanism 
mediated by IL-6 is involved in the pathogenesis of this plas- 
Figure 3.  Inhibition  of phsmacytoma cell growth by anti-IL-6  Ab, anti- 
IL-6P, mAb, and anti-gp130 mAb. (-4) The cells (2  x  10s/200/~l/well) 
were cultured with goat anti-lL-6 antiserum (10- s dilution), humanized 
antiqL-6tL mAb (10/~g/ml), or control Abs in the presence or absence 
of IL-6 (10 ng/ml). Goat anti-IL-6 antiserum and humanized anti-IL-6R 
mAb inhibited both the spontaneous and Ib6-induced proliferation of 
the cells. (B) The cells (6  x  104/200/~l/weU)  were cultured with  10 
ng/ml of OSM, LIF, and IL-6 in the presence of anti-gpD0 mAb or con- 
trol mAb (10/~g/ml). Anti-gpD0 mAb inhibited the spontaneous and 
augmented growth of the cells by OSM, LIF, and IL-6. 
macytoma case, as previously reported by Kawano et al. (4). 
In contrast,  Klein et al. (5) demonstrated paracrine but not 
autocrine regulation of the growth and differentiation of  my- 
eloma cells by IL-6 secreted from the stroma of the bone 
marrow in patients.  Since it is very difficult to identify the 
IL-6-producing cells and the cells responding to IL-6 in the 
marrow cells of those with multiple myeloma, we took ad- 
vantage of an extrameduUary plasmacytoma to obtain an ex- 
tremely pure population of  plasmacytoma cells in this study. 
Furthermore, an increased proportion of the plasmacytoma 
cells undergoing mitosis was observed after in vitro culture 
both in the presence and absence of exogenous IL-6 (data 
not shown), thus confirming an autocrine growth mecha- 
nism.  Although both IL-6R and gpD0 were expressed at 
a low level, the cells  dearly responded to IL-6, LIF, and OSM, 
suggesting that even  relatively  small number of  receptors could 
transduce enough signals to generate a growth response. 
The proliferation of freshly isolated plasmacytoma cells  was 
inhibited in vitro by a humanized anti-IL-6R mAb, rhPM1. 
The inhibitory effect of rhPM1 was as strong as that of the 
polyctonal anti-IL-6 Ab even in the presence of additional 
IL-6. Blockade by anti-IL-6R mAb has been reported previ- 
ously on myeloma cell lines (19), but not on freshly isolated 
human cells. 
The plasmablastic features and the expression of CD38, 
CD54, and CD56 but no VLA-5 antigens on these plasmacy- 
toma cells are consistent with a previously reported pheno- 
type of immature myeloma cells that grow in response to 
IL-6 (24). The loss of  the VLA-5 antigen on this extramedul- 
lary plasmacytoma suggests that VLA-5 as well as CD54 (in- 
tercellular adhesion molecule 1) and CD56 (neural cell adhe- 
sion molecule) may play a role in the interactions with marrow 
stromal  cells (24-26). 
Functional  pleiotropy  and redundancy, common charac- 
teristics of  cytokines, can be explained by interactions between 
multiple ligand-binding receptors and a common signal trans- 
ducer that lacks direct tigand-binding activity (12, 13). We 
demonstrated that OSM and LIF stimulated  the growth of 
freshly isolated human plasmacytoma cells as well as IL-6. 
Such activity which had never been demonstrated  before, had 
been anticipated since these cytokines share the gp130 pro- 
tein as a common signal transducer.  The blockade of the 
OSM-, LIF-, and IL-6-dependent growth of  the cells by anti- 
gp130 mAb confirmed that gpD0 was actually used as a 
common signal transducer for all of  these cytokines in freshly 
isolated plasmacytoma cells. The in vitro stimulatory activity 
on cell growth differed among these cytokines, as shown in 
Fig. 1. IL-6 appeared less effective  than OSM and LIF in this 
particular case. This may be explained  by the number ofligand- 
binding receptors specific for each cytokine. Another pos- 
sible explanation may be that the cells were already stimu- 
lated by endogenous IL-6 and were therefore less sensitive 
to exogenous IL-6. On the other hand, IL-I1 did not stimu- 
late the growth of the cells in this study. This result is con- 
sistent with a report by Paul et al. (23), and is probably due 
to the absence of IL-11K on the cell surface. Little syner- 
gistic effect among these cytokines was observed. This might 
be explained by the competitive  occupation of a common 
1345  Nishimoto et al.  Brief Definitive Report signal transducer.  The evidence that anti-gp130 mAb inhibited 
the spontaneous growth of these cells as much as anti-IL-6R 
mAb and that  no detectable level of OSM or LIF was ob- 
served in the culture supernatant of these cells suggests that 
no autocrine mechanism by OSM or LIF was active in this case. 
Our data suggest the potential therapeutic application of 
anti-IL-6R mAb and anti-gp130 mAb to this disease, although 
we do not yet know which cytokine is the major growth 
stimulator  in vivo. Since OSM and LIF are found in vivo 
(27, 28), anti-gp130 mAb may be therapeutically more effec- 
tive than anti-IL-6R mAb. In some cases of myeloma/plas- 
macytoma, no stimulatory effect with any of the cytokines 
except IL-6 was observed (data not shown).  Therefore, we 
propose that  myeloma cases could be classified  into one of 
three groups according to their response to these cytokines: 
(a) myeloma cells whose growth is dependent on IL-6 only; 
(b) myeloma cells whose growth is dependent on OSM, LIF, 
and IL-6; and (c) myeloma cells whose growth is indepen- 
dent of OSM, LIF, and IL-6. We did not test CNTF in this 
case. CNTF may also have the same activity on plasmacy- 
toma cells,  if the CNTF binding  receptor is expressed. 
Several reports have suggested that  the malignant  trans- 
formation into myeloma cells might  occur in immature  B 
cells (29, 30). We do not know whether such precursor cells 
of myeloma are vulnerable to anti-IL-6R mAb or anti-gp130 
mAb, which would influence the therapeutic efficacy of these 
antibodies. Furthermore,  the use of these antibodies in vivo 
may cause unpredictable  effects because of the  functional 
pleiotropy of these cytokines. Nonetheless, these experiments 
have provided useful information regarding the therapeutic 
application  of these  antibodies  to  human  myeloma/plas- 
macytoma. 
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